日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease

评论文章:用于治疗炎症性肠病的抗 β7 整合素疗法 etrolizumab 的非临床和临床药理学、药代动力学和药效学

M T Tang, M E Keir, R Erickson, E G Stefanich, F K Fuh, T Ramirez-Montagut, J M McBride, D M Danilenko

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes

针对 β7 整合素的人源化单克隆抗体选择性阻断 T 淋巴细胞的肠道归巢

E G Stefanich, D M Danilenko, H Wang, S O'Byrne, R Erickson, T Gelzleichter, H Hiraragi, H Chiu, S Ivelja, S Jeet, S Gadkari, O Hwang, F Fuh, C Looney, K Howell, V Albert, M Balazs, C Refino, S Fong, S Iyer, M Williams